The Price Is Right For LifeStance Health Group, Inc. (NASDAQ:LFST)
The Price Is Right For LifeStance Health Group, Inc. (NASDAQ:LFST)
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S") below 1.1x, you may consider LifeStance Health Group, Inc. (NASDAQ:LFST) as a stock to potentially avoid with its 2.4x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.
当美国医疗保健行业将近一半的公司的市售比率(或 “P/S”)低于1.1倍时,你可以考虑LifeStance Health Group, Inc.(纳斯达克股票代码:LFST)作为其2.4倍市盈率可能避开的股票。但是,市盈率之高可能是有原因的,需要进一步调查以确定其是否合理。
View our latest analysis for LifeStance Health Group
查看我们对LifeStance 健康集团的最新分析
![](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20231206/0-40c668cf7d7891520be8f6dac31dab0e-0-82379d88642e9b30bf460468e6d4e86a.png/big)
NasdaqGS:LFST Price to Sales Ratio vs Industry December 6th 2023
纳斯达克GS: LFST 与行业的股价销售比率 2023 年 12 月 6 日
What Does LifeStance Health Group's P/S Mean For Shareholders?
LifeStance Health Group的市盈率对股东意味着什么?
Recent times have been advantageous for LifeStance Health Group as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.
最近对LifeStance Health Group来说是有利的,因为其收入的增长速度快于大多数其他公司。看来许多人预计强劲的收入表现将持续下去,这提高了市盈率。但是,如果不是这样,投资者可能会陷入为股票支付过多费用的困境。
Want the full picture on analyst estimates for the company? Then our free report on LifeStance Health Group will help you uncover what's on the horizon.
想全面了解分析师对公司的估计吗?然后,我们关于LifeStance Health Group的免费报告将帮助您发现即将发生的事情。
Do Revenue Forecasts Match The High P/S Ratio?
收入预测与高市盈率相匹配吗?
LifeStance Health Group's P/S ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the industry.
LifeStance Health Group的市盈率对于一家有望实现稳健增长且重要的是表现优于行业的公司来说是典型的。
If we review the last year of revenue growth, the company posted a terrific increase of 22%. Pleasingly, revenue has also lifted 166% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.
如果我们回顾一下去年的收入增长,该公司公布了22%的惊人增长。令人高兴的是,得益于过去12个月的增长,总收入也比三年前增长了166%。因此,股东们肯定会对这些中期收入增长率表示欢迎。
Looking ahead now, revenue is anticipated to climb by 16% during the coming year according to the seven analysts following the company. Meanwhile, the rest of the industry is forecast to only expand by 7.3%, which is noticeably less attractive.
根据关注该公司的七位分析师的说法,展望未来,来年收入预计将增长16%。同时,预计该行业的其余部分将仅增长7.3%,这明显降低了吸引力。
In light of this, it's understandable that LifeStance Health Group's P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
有鉴于此,可以理解的是,LifeStance Health Group的市盈率高于大多数其他公司。看来大多数投资者都期待未来的强劲增长,并愿意为该股支付更多费用。
The Final Word
最后一句话
While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
尽管市销比不应该成为决定你是否买入股票的决定性因素,但它是衡量收入预期的有力晴雨表。
Our look into LifeStance Health Group shows that its P/S ratio remains high on the merit of its strong future revenues. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.
我们对LifeStance Health Group的调查表明,由于其未来收入强劲,其市盈率仍然很高。目前,股东们对市盈率感到满意,因为他们非常有信心未来的收入不会受到威胁。除非这些条件发生变化,否则它们将继续为股价提供强有力的支撑。
We don't want to rain on the parade too much, but we did also find 1 warning sign for LifeStance Health Group that you need to be mindful of.
我们不想在游行队伍中下太多雨,但我们也为LifeStance Health Group找到了一个需要注意的警告信号。
It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
重要的是要确保你寻找一家优秀的公司,而不仅仅是你遇到的第一个想法。因此,如果盈利能力的增长与你对一家优秀公司的想法一致,那就来看看这份免费名单吧,列出了最近收益增长强劲(市盈率低)的有趣公司。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。